SpringWorks Therapeutics, Inc. (SWTX) shares plummeted 5.04% intraday on Tuesday, underperforming the broader market, as concerns arose over the profitability of a potential acquisition by German pharmaceutical giant Merck KGaA.
Reports surfaced on Monday that Merck KGaA is in advanced talks to acquire the U.S. cancer and rare diseases drugmaker SpringWorks Therapeutics. However, analysts have raised questions about the deal's potential impact on Merck's profitability.
Equita analyst Davide Marchesin noted that while the acquisition could boost Merck's cancer-treatment pipeline, "one critical question would be if the acquisition would be accretive from year one." Marchesin highlighted that SpringWorks is currently loss-making despite generating over 350 million euros in annual revenue, potentially casting doubt on the deal's immediate financial benefit for Merck.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.